Compare Conagra Brands Inc (CAG) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Conagra Brands Inc trades at $14.08 (market cap $6.77B), while Ginkgo Bioworks Holdings Inc trades at $9.01 (market cap $590.53M). The key difference: Conagra Brands Inc is far larger — about 11.5× Ginkgo Bioworks Holdings Inc's market cap, and Conagra Brands Inc pays a 9.89% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CAG | DNA | |
|---|---|---|
Market Cap | $6.77B | $590.53M |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $16.14 |
52-Week Low | $12.58 | $5.48 |
Enterprise Value | $14.05B | $627.78M |
Dividend Yield | 9.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.33, up 3.62% today, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, missing Q2 2025 and Q1 2026 estimates but beating Q3 2025. Valuation ratios appear attractive with P/E of 10.06 and P/B of 0.84, though net income margin is negative at -0.39%. Recent news highlights upcoming Q4 earnings and dividend sustainability concerns under new leadership.
CAG presents a high-yield opportunity with a 10% dividend, but faces risks from potential dividend cuts, high debt, and revenue pressures. Analyst consensus is cautious with a $13.70 price target below current levels. Investors should weigh the defensive staple positioning against fundamental headwinds and earnings volatility for balanced risk-reward assessment.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
